| Name | [(E)-4-amino-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid |
|---|---|
| Synonyms | 2-Amino-4-methyl-5-phosphono-3 pentenoic acid carboxyethyl ester |
| Description | CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity[1]. CGP 39551 shows measurable inhibitory activity at both L-[3H]-glutamate (Ki=8.4 μM)[2]. |
|---|---|
| Related Catalog | |
| In Vitro | CGP 39551 inhibits the binding of the selective NMDA receptor antagonist, [3H]-CPP to rat brain postsynaptic densities (PSDs) with a Ki of 310 nM[2]. |
| In Vivo | CGP 39551 exhibits maximal electroshock-induced seizures in mice with the ED50 of 4 mg/kg (p.o.)[2]. Following chronic neonatal treatment with CGP 39551, adult rats show increased behavioral responses to the D2 dopamine receptor stimulation[3]. |
| References |
| Density | 1.312 g/cm3 |
|---|---|
| Boiling Point | 434.1ºC at 760 mmHg |
| Melting Point | 236-239ºC |
| Molecular Formula | C8H16NO5P |
| Molecular Weight | 237.19 |
| Flash Point | 216.3ºC |
| Exact Mass | 237.07700 |
| PSA | 119.66000 |
| LogP | 0.70110 |
| Vapour Pressure | 9.46E-09mmHg at 25°C |
| Index of Refraction | 1.512 |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| RIDADR | UN 2811 6.1 / PGIII |
| Precursor 5 | |
|---|---|
| DownStream 1 | |